World Equity Group Inc. Makes New $211,000 Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

World Equity Group Inc. acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,000 shares of the biopharmaceutical company’s stock, valued at approximately $211,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. State Street Corp raised its position in shares of TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after acquiring an additional 2,398,015 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after acquiring an additional 725,371 shares during the last quarter. Braun Stacey Associates Inc. bought a new stake in shares of TG Therapeutics during the fourth quarter worth $13,328,000. Castellan Group bought a new stake in shares of TG Therapeutics during the fourth quarter worth $8,539,000. Finally, Public Sector Pension Investment Board bought a new stake in shares of TG Therapeutics during the third quarter worth $6,619,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on TGTX shares. StockNews.com downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. JPMorgan Chase & Co. boosted their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. TD Cowen started coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price for the company. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Wednesday, January 15th. Finally, The Goldman Sachs Group upped their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, TG Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Trading Down 6.0 %

NASDAQ TGTX opened at $29.02 on Tuesday. The stock has a 50-day simple moving average of $30.96 and a 200 day simple moving average of $27.90. The company has a market capitalization of $4.52 billion, a PE ratio of -290.17 and a beta of 2.26. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $36.84.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.